We have developed a disruptive biotech nanotechnology which creates remote-controlled stem cells - technology which is at the cusp of beginning Phase 1 clinical trials after successful pre-clinical trials.

​

The technology answers the fundamental problem of selective stem cell differentiation. Stem cells in their current form are placed into a patient with the hope that they create the desired tissue purely based on their environment - which has a high failure rate. Through nanotechnology, we developed Remote-Controlled Stem Cell Technology, which allows clinicians to select the type of tissue they would like to create in situ. We are focussing first on spinal fusion.

 

Future Applications:

 

• Oncology

• Neurodegenerative disease

• Arthritis

• Tendon repair

• Orthopaedics

• Spinal cord repair.
   

We are aiming to finally unlock the world of potential that stem cell therapies have been promising.

​

The technology has the potential to revolutionise the areas of regenerative medicine and stem cell therapies; the underpinning facilitator of this technology has won the Nobel Prize in Chemistry in 2021!

​

We have recently concluded our successful pre-clinical trials and are gearing up to start Phase 1 human trials; paving the way to transforming the lives of patients around the world. The initial therapy area we focus our attention on is Spinal Fusion - changing what is currently an invasive surgery, into an outpatient injection procedure!

​​

​

How does the cell therapy work?

​

1) Nanoparticles with a magnetic core, coated with a biocompatible layer, are linked to one or more binding molecules. 

2) The tagged nanoparticles bind to ion-channels or other molecular receptors on the cell membrane. 

3) By subjecting the cells to a time-varying magnetic field, energy is transferred to the magnetic particles, which causes the specific receptor to be activated. 
 

4) This leads to protein regulation and controlled cell responses.